Fortress Biotech, Inc. ("Fortress" or "the Company") is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress plans to develop and commercialize products that it acquires both directly as well as indirectly by establishing subsidiary companies, also known as Fortress Companies. The Company will leverage its biopharmaceutical business expertise and drug development capabilities to help the Fortress Companies achieve their goals. Additionally, the Company will provide funding and management services to each of the Fortress Companies and from time to time the Company and the Fortress Companies will seek licensing, partnerships, joint ventures, and/or public and private financings to accelerate and provide additional funding to support their research and development programs.
November 9, 2015:
August 10, 2015:
July 17, 2015:
Fortress Biotech Subsidiary, Escala Therapeutics, Acquires NIH License and CRADAs Relating to the Development of N-acetyl-D-mannosamine (ManNAc) for Rare Genetic Disorders
May 11, 2015: